Compare LC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LC | IMCR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2014 | 2021 |
| Metric | LC | IMCR |
|---|---|---|
| Price | $19.96 | $36.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $22.67 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 1.5M | 333.0K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $1,296,102,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | $16.10 | $10.50 |
| P/E Ratio | $22.32 | ★ N/A |
| Revenue Growth | 16.98 | ★ 28.11 |
| 52 Week Low | $7.90 | $23.15 |
| 52 Week High | $20.94 | $40.72 |
| Indicator | LC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 49.05 |
| Support Level | $18.98 | $35.35 |
| Resistance Level | $20.94 | $40.71 |
| Average True Range (ATR) | 0.68 | 1.82 |
| MACD | 0.23 | -0.45 |
| Stochastic Oscillator | 78.92 | 22.55 |
LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.